HOME
>
臨床医学：内科
>
循環器一般
> DATA　UPDATE　CARDIOVASCULAR　4th　EDITION(循環系　第4版)

DATA　UPDATE　CARDIOVASCULAR　4th　EDITION(循環系　第4版)

出版社：	先端医学社
著者：	小川聡／監修
発行日：	2009-05-25
分野：	臨床医学：内科 > 循環器一般
ISBN：	9784884075590
電子書籍版：	2009-05-25 （第4版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

5,170 円(税込)

購入する

電子書籍

章別単位で購入

ブラウザ、アプリ閲覧

2,585 円(税込)

購入する

商品紹介

専門書などに出てくる頻度の高い、科学的根拠にもとづく医療を行ううえで重要な臨床試験を中心に選び解説。循環器系の大規模臨床試験の目的から具体的な方法、結果の見方までわかりやすく示す。最新のデータに対応した第4版。

目次

DATA UPDATE　CARDIOVASCULAR 4th EDITION（循環系　第4版）

―目次―

■心臓
【心不全】
【不整脈】
【急性冠動脈疾患】
【慢性冠動脈疾患】

■高血圧

■脳血管障害

■腎機能障害

■脂質異常症・動脈硬化

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[ 心臓 ]

P.15 掲載の参考文献

1) Costanzo MR et al : The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure : a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am Heart J 154 : 267-277, 2007

2) Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure : a randomized controlled trial. JAMA 287 : 1531-1540, 2002

P.17 掲載の参考文献

1) Cleland JG et al ; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators : The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 : 1539-1549, 2005

2) Abraham WT et al ; MIRACLE Study Group : Cardiac resynchronization in chronic heart failure. N Engl J Med 346 : 1845-1853, 2002

3) Bristow MR et al ; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 : 2140-2150, 2004

4) McAlister FA et al : Systematic review : cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 141 : 381-390, 2004

P.19 掲載の参考文献

1) Willenheimer R et al ; CIBIS III Investigators : Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence : results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) IH. Circulation 112 : 2426-2435, 2005

P.21 掲載の参考文献

1) Bristow MR et al ; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 : 2140-2150, 2004

2) Moss AJ et al ; Multicenter Automatic Defibrillator Impantation Trial H Investigators : Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 : 877-883, 2002

3) Kadish A et al ; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators : Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 : 2151-2158, 2004

4) Bardy GH et al : Sudden Cardiac Death in Hearth Failure Trial (SCD-HeFT) Investigators : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 : 225-237, 2005

P.23 掲載の参考文献

1) Kjekshus J ; CORONA Group : Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 : 2248-2261, 2007

2) Collins R et al : Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 : 757-767, 2004

3) Shepherd J et al : Pravastatin in elderly individuals at risk of vascular disease (PROSPER) : a randomized controlled trial. Lancet 360 : 1623-1630, 2002

4) GISSI-HF Investigators : Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial) : a randomized, double-blind, placebo-controlled trial. Lancet (Epub ahead of print)

P.25 掲載の参考文献

1) Anand I et al ; EARTH Investigators : Long-term effects of darusentan on left-ventricular remodeling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH) : randomized, double-blind, placebo-controlled trial. Lancet 364 : 347-354, 2004

2) Omland T et al : Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 89 : 1573-1579, 1994

3) Sakai S et al : Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384 : 353-355, 1996

P.27 掲載の参考文献

1) Bhatia RS et al : Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 : 260-269, 2006

2) Lee DS et al : Predicting mortality among patients hospitalized for heart failure : derivation and validation of a clinical model. JAMA 290 : 2581-2587, 2003

P.29 掲載の参考文献

1) Konstam MA et al ; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators : Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST Outcome Trial. JAMA 297 : 1319-1331, 2007

2) Gheorghiade M et al : Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure : Outcome Study with Tolvaptan (EVEREST). J Card Fail 11 : 260-269, 2005

3) Gheorghiade M et al : Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators : Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : the EVEREST Clinical Status Trials. JAMA 297 : 1332-1343, 2007

P.32 掲載の参考文献

1) Beshai JF et al ; Rethin Q Study Investigators : Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 357 : 2461-2471, 2007

2) Bradley DJ et al : Cardiac resychronization and death from progressive heart failure : a meta-analysis of randomized controlled trials. JAMA 289 : 730-740, 2003

P.35 掲載の参考文献

1) Bardy GH et al : Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 : 225-237, 2005

2) Brady GHI et al : Sudden Cardiac Death-Heart Failure Trial (SCD-HeFT). In : Arrhythmia treatment and therapy : evaluation of clinical trial evidence, ed by Woosley RL, Singh SN, Marcel Dekker, New York, 2000, 323-342

3) Doval HC et al : Randomized trial of low-dose amiodarone in sever congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 344 : 493-498, 1994

P.37 掲載の参考文献

1) Jourdain P et al : Plasma brain natriuretic peptideguided therapy to improve outcome in heart failure : the STARS-BNP Multicenter Study. J Am Coll Cardiol 49 : 1733-1739, 2007

2) Troughton RW et al : Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 : 1126-1130, 2000

P.39 掲載の参考文献

1) Mebazaa A et al ; SURVIVE Investigators : Levosimendan vs dobutamine for patients with acute decompensated heart failure : the SURVIVE Randomized Trial. JAMA 297 : 1883-1891, 2007

P.41 掲載の参考文献

1) McMurray JJ et al ; VERITAS Investigators : Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure : the VERITAS randomized controlled trials. JAMA 298 : 2009-2019, 2007

2) Kaluski E et al : RITZ-5 : randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema : a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 41 : 204-210, 2003

P.43 掲載の参考文献

1) ACTIVE Writing Group of the ACTIVE Investigators et al : Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W) : arandomised controlled trial. Lancet 367 : 1903-1912, 2006

P.45 掲載の参考文献

1) Roy D et al ; Atrial Fibrillation and Congestive Heart Failure Investigators : Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 : 2667-2677, 2008

P.47 掲載の参考文献

1) Pappone C et al : A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation : the APAF Study. J Am Coll Cardiol 48 : 2340-2347, 2006

P.50 掲載の参考文献

1) Mant J et al ; BAFTA investigators : Midland Research Practices Network (MidReC) : Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of The Aged Study, BAFTA) : a randomized controlled trial. Lancet 370 : 493-503, 2007

2) Yasaka M et al : Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 40 : 1183-1188, 2001

P.53 掲載の参考文献

1) Kadish A et al : Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators : Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 : 2151-2158, 2004

P.55 掲載の参考文献

1) Hohnloser SH et al ; DINAMIT Investigators : Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 : 2481-2488, 2004

2) Wilber DJ et al : Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 109 : 1082-1084, 2004

3) Poole JE et al : Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 359 : 1009-1017, 2008

P.57 掲載の参考文献

1) Singh BN et al ; EURIDIS and ADONIS Investigators : Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 357 : 987-999, 2007

P.59 掲載の参考文献

1) Olshansky B et al : Is dual-chamber programming inferior to single-chamber programming in an implantable cardioverter-defibrillator? Results of the INTRINSIC RV (Inhibition of Unnecessary RV Pacing With AVSH in ICDs) study. Circulation 115 : 9-16, 2007

P.61 掲載の参考文献

1) Da Costa A et al ; Loire-Ardeche-Dome-Isere-Puy-de-Dome Trial on Atrial Flutter Investigators : Result from the Loire-Ardeche-Dome-Isere-Puy-de-Dome (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. Circulation 114 : 1676-1681, 2006

P.63 掲載の参考文献

1) Connolly SJ et al ; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators : Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators : the OPTIC Study : a randomized trial. JAM4. 295 : 165-171, 2006

P.67 掲載の参考文献

1) Singh BN et al ; Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators : Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352 : 1861-1872, 2005

2) Roy D et al : Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342 : 913-920, 2000

P.69 掲載の参考文献

1) Sweeney MO et al ; Search AV Extension and Managed Ventricular Pacing for Promoting Atrioven-tricular Conduction (SAVE PACe) Trial : Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med 357 : 1000-1008, 2007

2) Wilkoff BL et al : Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator : the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 288 : 3115-3123, 2002

3) Sweeney MO et al : Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 107 : 2932-2937, 2003

P.71 掲載の参考文献

1) Dorian P et al : SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators : Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 110 : 3646-3654, 2004

P.73 掲載の参考文献

1) Reddy VY et al : Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 357 : 2657-2665, 2007

P.75 掲載の参考文献

1) Brouwer IA et al ; SOFA Study Group : Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators : the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 295 : 2613-2619, 2006

P.77 掲載の参考文献

1) Albers GW et al ; SPORTIF Executive Steering Committee for the SPORTIF V Investigators : Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation : a randomized trial. JAMA 293 : 690-698, 2005

P.80 掲載の参考文献

1) Stone GW et al ; ACUITY Investigators : Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 : 2203-2216, 2006

2) Stone GW et al : Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial : study design and rationale. Am Heart J 148 : 764-775, 2004

P.83 掲載の参考文献

1) Camm AJ et al : AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators : Mortality in patients after a recent myocardial infarction : a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 109 : 990-996, 2004

2) Sakaki K et al : Time-domain T-wave alternans measured from Holter electrocardiograms predicts cardiac mortality in patients with left ventricular dysfunction : A prospective study. Heart Rhythm 6 : 332-337, 2009

3) Miwa Y et al : Heart rate turbulence as a predictor of cardiac mortality and arrhythmic events in patients with dilated cardiomyopathy : A prospective study. J Cardiovasc Electrophysiol 2009, Epub ahead of print

P.85 掲載の参考文献

1) APEX AMI Investigators et al : Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing Primary percutaneous coronary intervention : a randomized controlled trial. JAMA 297 : 43-51, 2007

2) Granger CB et al : Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary Intervention In acute myocardial infarction : the complement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 108 : 1184-1190, 2003

P.87 掲載の参考文献

1) Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4PCI) Investigators : Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4PCI) : randomised trial. Lancet 367 : 569-578, 2006

P.89 掲載の参考文献

1) Schomig A et al ; Beyond 12 hours Reperfusion Aiternative Evaluation (BRAVE-2) Trial Investigators : Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset : a randomized controlled trial. JAMA 293 : 2865-2872, 2005

2) Kimura A et al : Myocardial salvage by reperfusion 12 hours after coronary ligation in dogs. Jpn Circ J 62 : 294-298, 1998

3) Gibbons RJ et al : Acute PCI for ST-segment elevation myocardial infarction. is later better than never? JAMA 293 : 2930-2932, 2005

P.91 掲載の参考文献

1) Di Mario C et al ; CARESS-in-AMI (Combined Abciximab RE-teplase Stent Study in Acute Myocardial Infarction) Investigators : Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI) : an open, prospective, randomised, multicentre trial. Lancet 371 : 559-568, 2008

P.93 掲載の参考文献

1) Sabatine MS et al ; CLARITY-TIMI 28 Investigators : Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 : 1179-1189, 2005

P.95 掲載の参考文献

1) Chen ZM et al ; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group : Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction : randomised placebo-controlled trial. Lancet 366 : 1607-1621, 2005

2) Chen ZM et al ; COMMIT (CIOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group : Early intravenous then oral metoprolol in 45, 852 patients with acute myocardial infarction : randomised placebo-controlled trial. Lancet 366 : 1622-1632, 2005

P.97 掲載の参考文献

1) Yusuf S et al ; CREATE Trial Group Investigators : Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAM 1293 : 427-435, 2005

2) Mehta SR et al : CREATE-ECLA Trial Group Investigators : Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction : the CRE-ATE-ECLA randomized controlled trial. JAMA 293 : 437-446, 2005

P.99 掲載の参考文献

1) Mehta SR et al ; CREATE-ECLA trial group investigators : Effect of glucose-insulinっotassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction : the CREATE-ECLA randomized controlled trial. JAMA 293 : 437-446, 2005

2) van der Horst IC et al ; Zwolle Infarct Study Group : Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction : the glucose-insulin-potassium study : a randomized trial. J Am Coll Cardiol 42 : 784-791, 2003

P.101 掲載の参考文献

1) Bhatt DL et al : CRUSADE Investigators : Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes : results from the CRUSADE Quality Improvement Initiative. JAMA 292 : 2096-2104, 2004

P.103 掲載の参考文献

1) Tardif JC et al ; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators : Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis : a randomized controlled trial. JAMA 297 : 1675-1682, 2007

2) TardifJC et al ; Avasimibe and Progression of Lesions on Ultra Sound (A-PLUS) Investigators : Effects of the acyl coenzyme A : cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 110 : 3372-3377, 2004

3) Calabresi L et al : Molecular characterization of native and recombinant apolipoprotein A-I Milano dimer. The introduction of an interchair disulfied bridge remarkably alters the physicochemical properties of apolipoprotein A-I. J Biol Chem 269 : 32168-32174, 1994

4) Nissen SE et al : Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes : a rondomized controlled trial. JAMA 290 : 2292-2300, 2003

P.106 掲載の参考文献

1) Okazaki S et al : Early statin treatment in patients with acute coronary syndrome : demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event : the ESTABLISH Study. Circulation 110 : 1061-1168, 2004

2) Schwartz GG et al ; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators : Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes : the MIRACL study : arandomized controlled trial. JAMA 285 : 1711-1718, 2001

3) Grundy SM et al ; National Heart, Lung, and Blood Institute ; American College of Cardiology Foundation ; American Heart Association : Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 : 227-239, 2004

P.109 掲載の参考文献

1) Antman EM et al ; ExTRACT-TIMI 25 Investigators : Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 : 1477-1488, 2006

P.111 掲載の参考文献

1) Fox KA et al ; GRACE Investigators : Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 297 : 1892-1900, 2007

2) Fox KA et al ; GRACE Investigators : From guide-lines to clinical practice : the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 : 1414-1424, 2003

P.113 掲載の参考文献

1) de Winter RJ et al ; Invasive Versus Conservative Treatment in Unstable Coronary Syndrome (ICTUS) : Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 353 : 1095-1104, 2005

2) Fox KA et al : Randomized Intervention Trial of unstable Angina Investigators : Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction : the British Heart Foundation RITA 3 randomised trial. Randomized Interventional Trial of Unstable Angina. Lancet 360 : 743-751, 2002

3) Braunwald E et al ; American Heart Association. Committee on the Management of Patients With Unstable Angina : ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarctionrsummary article : a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40 : 1366-1374, 2002

P.115 掲載の参考文献

1) Barter PJ et al ; ILLUMINATE Investigators : Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 : 2109-2122, 2007

2) Linsel-Nitschke P et al : HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4 : 193-205, 2005

3) Gordon DJ et al : High-density lipoprotein cholesterol and cardiovascular disease : Four prospective American studies. Circulation 79 : 8-15, 1989

4) Barter P et al ; Treating to New Targets Investigators : HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. M Engl J Med 357 : 1301-1310, 2007

5) Nissen SE et al : ILLUSTRATE Investigators : Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 : 1304-1316, 2007

6) Kastelein JJ et al : RADIANCE 1 Investigators : Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 : 1620-1630, 2007

7) Bots ML et al ; RADIANCE 2 Investigators : Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study) : a randomised, double-blind trial. Lancet 370 : 153-160, 2007

P.117 掲載の参考文献

1) Kastrati A et al ; Intracoronary Stenting and Antithrombotic : Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators : Abciximab in patients with acute coronary syndromes undergoing Percutaneous coronary intervention after clopidogrel pretreatment : the ISAR-REACT 2 randomized trial. JAMA 295 : 1531-1538, 2006

2) Schulman SP : Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. JAMA 292 : 1875-1882, 2004

3) Yusuf S et al : The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators : Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 : 494-502, 2001

4) Kandzari DE et al ; ISAR-REACT Study Investigators : Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 44 : 2133-2136, 2004

5) Kastrati A et al : lntracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators : A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 : 232-238, 2004

P.119 掲載の参考文献

1) Kitakaze M et al ; J-WIND investigators : Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND) : two randomised trials. Lancet 370 : 1483-1493, 2007

P.121 掲載の参考文献

1) Morrow DA et al ; MERLIN-TIMI 36 Trial Investigators : Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes : the MERLIN-TIMI 36 randomized trial. JAMA 297 : 1775-1783, 2007

P.123 掲載の参考文献

1) Bonaa KH et al ; NORVIT Trial Investigators : Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 : 1578-1588, 2006

2) Lonn E et al ; The Heart Outcomes Prevention Evaluation (HOPE) 21nvestigators : Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 : 1567-1577, 2006

P.125 掲載の参考文献

1) Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators et al : Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 : 1464-1476, 2006

P.127 掲載の参考文献

1) Yusuf S et al ; OASIS-6 Trial Group : Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction : the OASIS-6 randomized trial. JAMA 295 : 1519-1530, 2006

P.129 掲載の参考文献

1) Hochman JS et al ; Occluded Artery Trial Investigators : Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 355 : 2395-2407, 2006

P.131 掲載の参考文献

1) Laarman GJ et al : Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 : 1105-1113, 2006

2) Spaulding C et al ; TYPHOON Investigators : Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 : 1093-1104, 2006

P.133 掲載の参考文献

1) Cannon CP et al ; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators : Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 : 1495-1504, 2004

2) Ridker PM et al ; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators : C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 : 20-28, 2005

P.135 掲載の参考文献

1) Gershlick AH et al : REACT Trial Investigators : Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 353 : 2758-2768, 2005

P.137 掲載の参考文献

1) Schachinger V et al ; REPAIR-AMI Investigators : Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355 : 1210-1221, 2006

2) Lunder K et al : Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 355 : 1199-1209, 2006

3) Rosenzweig A : Cardiac Cell Therapy-Mixed results from mixed cells. N Engl J Med 355 : 1274-1277, 2006

P.139 掲載の参考文献

1) Zohlnh6fer D et al ; REVIVAL-2 Investigators : Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction : a randomized controlled trial. JAMA 295 : 1003-1010, 2006

P.141 掲載の参考文献

1) Stenestrand U et al ; RIKS-HIA Registry : Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. JAMA 296 : 1749-1756, 2006

P.143 掲載の参考文献

1) Ripa RS et al : Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction : result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 113 : 1983-1992, 2006

P.145 掲載の参考文献

1) Ferguson JJ et al ; SYNERGY Trial Investigators : Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy : primary results of the SYNERGY randomized trial. JAMA 292 : 45-54, 2004

2) The GUSTO Investigators : An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction, N Engl J Med 329 : 673-682, 1993

3) Rao AK et al : Thrombolysis in Myocardial Infarction (TIMI) trial-phase I : hemorrhagic manifestations and changes in plasma fibrinogen and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11 : 1-11, 1988

P.147 掲載の参考文献

1) Spaulding C et al ; TYPHOON Investigators : Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 : 1093-1104, 2006

2) Kastrati A et al : Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 28 : 2706-2713, 2007

3) Mauri L et al : Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 359 : 1330-1342, 2008

4) Nakazawa G et al : Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients : an autopsy study. Circulation 118 : 1138-1145, 2008

P.149 掲載の参考文献

1) Strandberg TE et al : 4S Group : Mortality and incidence of cancer during 10-years follow-up of the Scandinavian Simvastation Survival Study (4S). Lancet 364 : 771-777, 2004

P.151 掲載の参考文献

1) Grayston JT et al ; ACES Investigators : Azithromycin for the secondary prevention of coronary events. N Engl J Med 352 : 1637-1645, 2005

2) O'Connor CM et al : Investigators in the WIZARD Study : Azithromycin for the secondary prevention of coronary heart disease events : the WIZARD study : a randomized controlled trial. JAMA 290 : 1459-1466, 2003

3) Cannon CP et al : Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 352 : 1646-1654, 2005

P.153 掲載の参考文献

1) Poole-Wilson PA et al ; A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators : Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial) : randomised controlled trial. Lancet 364 : 849-857, 2004

P.155 掲載の参考文献

1) Nissen SE et al ; ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVE) Investigators : Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 354 : 1253-1263, 2006

2) Kusunoki J et al : Acyl-CoA : cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 103 : 2604-2609, 2001

3) Accad M et al : Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA : cholesterol acyltransferase 1. J Clin Invest 105 : 711-719, 2000

P.157 掲載の参考文献

1) Hemmelgarn BR et al ; Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) Investigators : Survival after coronary revascularization among patients with kidney disease. Circulation 110 : 1890-1895, 2004

P.159 掲載の参考文献

1) Pasceri V et al : ARMYDA Investigators : Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention : results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 110 : 674-678, 2004

2) Schwartz GG et al : Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators : Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes : the MIRACL study : a randomized controlled trial. JAMA 285 : 1711-1718, 2001

P.161 掲載の参考文献

1) Nissen SE et al ; ASTEROID Investigators : Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. JAMA 295 : 1556-1565, 2006

P.163 掲載の参考文献

1) Nussmeier NA et al : Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 : 1081-1091, 2005

2) Ott E et al ; Ischemia Research and Education Foundation (IREF) Investigators : Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125 : 1481-1492, 2003

3) Bombardier C et al ; VIGOR Study Group : Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 : 1520-1528, 2000

4) FitzGerald GA : Coxibs and cardiovascular disease. N Engl J Med 351 : 1709-1711, 2004

P.165 掲載の参考文献

1) Nissen SE et al ; CAMELOT Investigators : Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure : the CAMELOT study : a randomized controlled trial. JAMA 292 : 2217-2225, 2004

P.167 掲載の参考文献

1) Chaitman BR et al ; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators : Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina : a randomized controlled trial. JAMA 291 : 309-316, 2004

2) Boden WE et al ; COURAGE trial research group : Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 : 1503-1516, 2007

3) Fujiwara H et al : Arandomized comparative multicenter study between PCI-medical and medicalpreceding therapies. S4-4 Japanese stable angina pectoris (JSAP) study : Inter J Cardiol 122 : S7, 2007

P.169 掲載の参考文献

1) Bhatt DL et al ; CHARISMA Investigators : Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 : 1706-1717, 2006

P.171 掲載の参考文献

1) Koo BK et al : Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial) : an open-label randomised controlled study. Lancet 370 : 567-574, 2007

P.173 掲載の参考文献

1) Boden WE et al ; COURAGE Trial Research Group : Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 : 1503-1516, 2007

2) Nishigaki K et al ; JSAP (Japanese Stable Angina Pectoris) Study Investigators : Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease : A randomized, comparative, multicenter study. J Am Coll Cardiol Intv 1 : 469-479, 2008

P.175 掲載の参考文献

1) Hannan EL et al : Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 358 : 331-341, 2008

2) Moses JW et al : SIRIUS Investigators : Sirolimus-eluting stents versus standard stents in patients with Stenosis in a native coronary artery. N Engl J Med 349 : 1315-1323, 2003

3) Serruys PW et al : Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease : the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 46 : 575-581, 2005

4) Hannan EL et al : Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 352 : 2174-2183, 2005

P.177 掲載の参考文献

1) Lansky AJ et al ; DELIVER Clinical Trial Investigators : Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions : angiographic follow-up of the DELIVER clinical trial. Circulation 109 : 1948-1954, 2004

2) Park SJ et al : A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 348 : 1537-1545, 2003

3) Gershlick A et al : Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent : the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 109 : 487-493, 2004

4) Stone GW et al : A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 : 221-231, 2004

5) Holmes DR Jr et al : Analysis of 1-year clinical outcomes in the SIRIUS trial : a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 : 634-640, 2004

P.179 掲載の参考文献

1) Fajadet J et al : ENDEAVOR II Investigators : Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions : clinical and angiographic results of the ENDEAVOR II trial. Circulation 114 : 798-806, 2006

2) Meredith IT et al ; ENDEAVOR Investigators : Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent : ENDEAVOR I, the first-in-human study. Am J Cardiol 100 : 56M-61M, 2007

3) Kandzari DE et al ; ENDEAVOR III Investigators : Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease : a randomized controlled trial. J Am Coll Cardiol 48 : 2440-2447, 2006

4) Pinto Slottow TL et al : Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the endeavor zotarolimus-eluting coronary stent. Circulation 117 : 1603-1608, 2008

P.181 掲載の参考文献

1) Win HK et al : EVENT Registry Investigators : Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 : 2001-2009, 2007

P.183 掲載の参考文献

1) Lonn E et al ; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators : Homocystein lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 : 1567-1577, 2006

2) Lonn E et al ; HOPE-2 Investigators : Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients : the Heart Out-comes Prevention Evaluation (HOPE) -2 trial. Can J Cardiol 22 : 47-53, 2006

P.185 掲載の参考文献

1) Nissen SE et al ; ILLUSTRATE Investigators : Effectof torcetrapib on the progression of coronary athero-sclerosis. N Engl J Med 356 : 1304-1316, 2007

2) Brousseau ME et al : Effect of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 : 1505-1515, 2004

3) Barter PJ et al ; ILLUMINATE Investigators : Effect of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 : 2109-2122, 2007

P.187 掲載の参考文献

1) Rouleau JL et al ; IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators : Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 117 : 24-31, 2008

2) Fox KM : EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators : Efficacy of peridopril in reduction of cardiovascular events among patients with stable coronary artery disease : randomized, double-blind, placebo-controlled, multi-centre trial (the EUROPA study). Lancet 362 : 782-788, 2003

3) Braunwald E et al : PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 : 2058-2068, 2004

P.189 掲載の参考文献

1) Kastrati A et al ; ISAR-DESIRE Study Investigators : Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis : a randomized controlled trial. JAMA 293 : 165-171, 2005

2) Waksman R et al : Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation 101 : 1895-1898, 2000

P.191 掲載の参考文献

1) Dibra A et al : ISAR-DIABETES Study Investigators : Paclitaxel-eluting or sirolimus eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 : 663-670, 2005

P.193 掲載の参考文献

1) Kastrati A et al ; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators : A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 : 232-238, 2004

P.195 掲載の参考文献

1) Kim YH et al : Long-DES-II Study Investigators : Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 114 : 2148-2153, 2006

2) Babapulle MN et al : A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 : 583-591, 2004

3) Park KH et al : Comparison of the effectiveness of sirolimus-and paclitaxel-eluting stents for small coronary artery lesions. Catheter Cardiovasc Interv 67 : 589-594, 2006

P.197 掲載の参考文献

1) Krucoff MW et al : Music, imagery, touch, and prayer as adjuncts to interventional cardiac care : the Monitoring and Actualisation of Noetic Trainings (MANTRA) II randomised study. Lancet 366 : 211-217, 2005

2) Krucoff MW et al : Integrative noetic therapies as adjuncts to percutaneous intervention during unstable coronary syndromes : Monitoring and Actualization of Noetic Training (MANTRA) feasibility pilot. Am Heart J 142 : 760-769, 2001

P.200 掲載の参考文献

1) Nakamura H et al ; MEGA Study Group : Primary prevention of cardiovascular disease with pravstatin in Japan (MEGA Study) : a prospective randomised controlled trial. Lancet 368 : 1155-1163, 2006

P.203 掲載の参考文献

1) Bild DE et al : Multi-ethnic study of atherosclerosis : objectives and design. Am J Epidemiol 156 : 871-881, 2002

2) Carr JJ et al : Calcified coronary artery plaque measurement with cardiac CT in population-based studies : standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology 234 : 35-43, 2005

3) Yaghoubi S et al : Offline assessment of atherosclerotic coronary calcium from electron beam tomograms. Am J Card Imaging 9 : 231-236, 1995

4) Detrano R et al : Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 358 : 1336-1345, 2008

P.205 掲載の参考文献

1) ONTARGET Investigators : Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 : 1547-1559, 2008

P.207 掲載の参考文献

1) Hausleiter J et al ; OSIRIS Investigators : Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis : the Oral Sirolimus to Inhibit Recurrent Instent Stenosis (OSIRIS) trial. Circulation 110 : 790-795, 2004

P.209 掲載の参考文献

1) Braunwald E et al : PEACE Trial Investigators : Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 : 2058-2068, 2004

2) Yusuf S et al : Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 : 145-153, 2000

3) Fox KM et al : Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease : randomized, double-blind, placebo-contrlled, multicentre trial (the EUROPA study). Lancet 362 : 782-788, 2003

P.211 掲載の参考文献

1) Verrier ED et al ; PRIMO-CABG Investigators : Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass ; a randomized trial. JAMA 291 : 2319-2327, 2004

P.213 掲載の参考文献

1) Suttorp MJ et al : Primary stenting of totally occluded native coronary arteries II (PRISON II) : a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 114 : 921-928, 2006

P.215 掲載の参考文献

1) Desai ND et al : Radial Artery Patency Study Investigators : A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med 351 : 2302-2309, 2004

2) Hayward PA et al : Effect of radiai artery or saphenous vein conduit for the second graft on 6-year clinical outcome after coronary artey bypass grafting. Results of a randomized trial. Eur J Cardiothorac Surg 34 : 113-117, 2008

P.217 掲載の参考文献

1) Marzocchi A et al : Long-term safety and efficacy of drug-eluting stents : two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation 115 : 3181-3188, 2007

2) Ortolani P et al : Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions : results from a real-world multicenter registry. Circulation 117 : 923-930, 2008

3) Moses JW et al ; SIRIUS Investigators : Sirolimus-eluting stents versus standard stents in patients with Stenosis in a native coronary artery. N Engl J Med 349 : 1315-1323, 2003

4) Daemen J et al : Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice : data from a large two-institutional cohort study. Lancet 369 : 667-678, 2007

P.219 掲載の参考文献

1) Morice MC et al ; REALITY Trial Investigators : Sirolimus-vs paclitaxel-eluting stents in de novo coronary artery lesions : the REALITY trial : a randomized controlled trial. JAMA 295 : 895-904, 2006

2) Brener SJ : Wish list and REALITY : choice of stents and end points for treatment of de novo coronary artery lesions. JAMA 295 : 937-938, 2006

3) Schomig A et al : A meta-analysis of 16 randomized trial of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 50 : 1373-1380, 2007

P.220 掲載の参考文献

1) Lemos PA et al : Unrestricted utilization of sirolimus-eluting-stents compared with conventional bare stent implantation in the "real world" : the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109 : 190-195, 2004

P.223 掲載の参考文献

1) Nissen SE et al ; REVERSAL Investigators : Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis : a randomized controlled trial. JAMA 291 : 1071-1080, 2004

P.225 掲載の参考文献

1) Barrett-Connor E et al ; Raloxifene Use for The Heart (RUTH) Trial Investigators : Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 : 125-137, 2006

P.227 掲載の参考文献

1) Deedwania P et al : Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease : Results of the Study Assessing Goals in the Elderly (SAGE). Circulation 115 : 700-707, 2007

2) Stone PH et al ; Vascular Basis Study Group : Effects of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease : the Vascular Basis for the Treatment of Myocardial Ischemia Study. Circulation 111 : 1747-1755, 2005

3) Nissen SE et al : REVERSAL Investigators : Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis : a randomized controlled trial. JAMA 291 : 1071-1080, 2004

4) Taylor AJ et al : ARBITER : Arterial Biology for the Investigation of the Treatment Effect of Reducing Cholesterol : a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106 : 2055-2060, 2002

5) LaRosa JC et al ; Treating to New Targets (TNT) Investigators : Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 : 1425-1435, 2005

P.229 掲載の参考文献

1) Cowell SJ et al ; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators : A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352 : 2389-2397, 2005

P.231 掲載の参考文献

1) Lagerqvist B et al : SCAAR Study Group : Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 : 1009-1019, 2007

P.233 掲載の参考文献

1) Ardissino D et al ; SES-SMART Investigators : Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries : a randomized trial. JAMA 292 : 2727-2734, 2004

P.235 掲載の参考文献

1) Windecker S et al : Sirolinus-eluting and paclitaxel-eluting stent for coronary revascularization. N Engl J Med 353 : 653-662, 2005

2) Dibra A et al ; ISAR-DIABETES Study Investigators : Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 : 663-670, 2005

3) Stone GW et al ; SPIRIT III Investigators : Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease : a randomized trial. JAMA 299 : 1903-1913, 2008

4) Galloe AM et al : SORT OUT II Investigators : Comparison of paclitaxel-and sirolimus-eluting stents in everyday clinical practice : the SORT OUT II randomized trial. JAMA 299 : 409-416, 2008

P.237 掲載の参考文献

1) Holmes DR Jr et al ; SISR Investigators : Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents : the SISR randomized trial. JAMA 295 : 1264-1273, 2006

2) Grise MA et al : Five-year clinical follow-up after intracoronary radiation : results of a randomized clinical trial. Circulation 105 : 2737-2740, 2002

3) Waksman R et al : Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Circulation 109 : 340-344, 2004

4) Moses JW et al ; SIRIUS Investigators : Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 : 1315-1323, 2003

5) Ellis SG et al ; TAXUS V ISR Investigators : Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis : the TAXUS V ISR trial. Eur Heart J 29 : 1625-1634, 2008

P.239 掲載の参考文献

1) Montalescot G et al ; STEEPLE Investigators : Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355 : 1006-1017, 2006

2) Stabile E et al : The CIAO (Coronary Interventions Antiplatelet-based Only) Study : a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol 52 : 1293-1298, 2008

P.241 掲載の参考文献

1) Simonton CA et al ; STENT Group : Comparative Clinical Outcomes of Paclitaxel-and Sirolimus-Eluting Stents : result from a arge prospective multicenter registry--STENT Group. J Am Coll Cardiol 50 : 1214-1222, 2007

P.243 掲載の参考文献

1) Windecker S et al : Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization : the TiNOX trial. Circulation 111 : 2617-2622, 2005

2) Windecker S et al ; Working Group on Novel Surface Coating of Biomedical Devices (SCOL) : Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation 104 : 928-933, 2001

3) Karjalainen PP et al : Titanium and nitride oxidecoated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population. J Invasive Cardiol 18 : 462-468, 2006

P.245 掲載の参考文献

1) LaRosa JC et al ; Treating to New Targets (TNT) Investigators : Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 : 1425-1435, 2005

P.247 掲載の参考文献

1) Assmus B et al : Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 355 : 1222-1232, 2006

P.249 掲載の参考文献

1) Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators ; Yusuf S et al : Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors : a randomized controlled trial. Lancet 372 : 1174-1183, 2008

2) The ONTARGET Investigators ; Yusuf S et al : Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 : 1547-1559, 2008

3) Yusuf S et al : Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342 : 145-153, 2000

P.251 掲載の参考文献

1) Warfarin Antiplatelet Vascular Evaluation Trial Investigators : Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357 : 217-227, 2007

[ 高血圧 ]

P.255 掲載の参考文献

1) Patel A et al ; ADVANCE Collaborative Group : Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial) : a randomised controlled trial. Lancet 370 : 829-840, 2007

P.258 掲載の参考文献

1) Sever PS et al : Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 19 : 1139-1147, 2001

2) Dahlof B et al ; ASCOT Investigators : Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) : a multicentre randomised controlled trial. Lancet 366 : 895-906, 2005

3) Poulter NR et al ; ASCOT Investigators : Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 366 : 907-913, 2005

P.261 掲載の参考文献

1) Ruggenenti P et al ; Bergamo Nephrologic Diabetes Conplications Trial (BENEDICT) Investigators : Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 : 1941-1951, 2004

2) Heller J et al : The effect of two different calcium antagonists on the glomerular haemodynamics in the dog. pflugers Arch 415 : 751-755, 1990

P.263 掲載の参考文献

1) Ogihara T et al ; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group : Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks : candesartan antihypertensive survival evaluation in Japan trial. Hypertension 51 : 393-398, 2008

2) Ogihara T et al ; CASE-J Trial Group : The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension : a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens Res 31 : 1595-1601, 2008

3) Ogihara T et al ; CASE-J Trial Group : ARB candesartan and CCB amlodipine in hypertensive patients : the CASE-J triaL Expert Rev Cardiovasc Ther 6 : 1195-1201, 2008

P.265 掲載の参考文献

1) Bakris GL et al ; GEMINI Investigators : Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension : a randomized controlled trial. JAMA 292 : 2227-2236, 2004

P.267 掲載の参考文献

1) Scholze J et al : Optimal treatment of obesity-related hypertension : the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 115 : 1991-1998, 2007

P.269 掲載の参考文献

1) Beckett NS et al ; HYVET Study Group : Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 : 1887-1898, 2008

2) Peters R et al ; HYVET Investigators : Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG) : a double-blind, placebo controlled trial. Lancet Neurol 7 : 683-689, 2008

P.271 掲載の参考文献

1) Makino H et al ; INNOVATION Study Group Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30 : 1577-1578, 2007

2) Makino H et al ; INNOVATION Study Group : Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes : a post-hoc analysis of The Incipient to Overt : Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hyperteens Res 31 : 657-664, 2008

P.273 掲載の参考文献

1) JATOS Study Group : Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertens Res 31 : 2115-2127, 2008

2) JATOS Study Group : The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS) : protocol, patient characteristics, and blood pressure during the first 12 months. Hypertens Res 28 : 513-520, 2005

P.275 掲載の参考文献

1) Ohkubo T et al : J-HOME Study Group : Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan : First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Hypertens Res 27 : 755-763, 2004

P.277 掲載の参考文献

1) Mochizuki S et al ; Jikei Heart Study Group : Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study) : a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369 : 1431-1439, 2007

2) Cohn JN et al : Rationale and design of the Valsartan Heart Failure Trial : alarge multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 5 : 155-160, 1999

3) Pfeffer MA et al ; CHARM Investigators and Committees : Effects of candesartan on mortality and morbidity in patients with chronic heart failure : the CHARM-Overall programme. Lancet 362 : 759-766, 2003

4) Dahlof B et al ; LIFE Study Investigators : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : a randomised trial against atenolol. Lancet 359 : 995-1003, 2002

P.279 掲載の参考文献

1) Schrader J et al ; MOSES Study Group : Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention : principal results of a prospective randomized controlled study (MOSES). Stroke 36 : 1218-1226, 2005

2) PROGRESS Collaborative Group : Randomised trial of aperidopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 : 1033-1041, 2001

P.281 掲載の参考文献

1) Marre M et al : Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes : the NESTOR Study. J Hypertens 22 : 1613-1622, 2004

2) Marre M et al : Effect of indapamide SR on microalbuminuria--the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia) --rationale and protocol for the main trial. J Hypertens Suppl 21 : S19-S24, 2003

3) Beckett NS et al ; HYVET Study Group : Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 : 1887-1898, 2008

4) Holman RR et al : Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359 : 1565-1576, 2008

P.283 掲載の参考文献

1) Hasebe N et al : NICE Combi Study Group : Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension : the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 23 : 445-453, 2005

2) Fujikawa K et al ; NICE-Combi Study Group : Cost-effectiveness analysis of hypertension treatment : controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension--the Nifedipine and Candesartan Combination (NICE-Combi) Study. Hypertens Res 28 : 585-591, 2005

P.285 掲載の参考文献

1) Appel LJ et al ; OmniHeart Collaborative Research Group : Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids : results of the OmniHeart randomized trial. JAMA 294 : 2455-2464, 2005

2) Appel LJ et al : A clinical trial of the effects of dietary patterns on blood pressure. DASH collaborative research group. N Engl J Med 336 : 1117-1124, 1997

3) Azadbakht L et al : Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care 28 : 2823-2831, 2005

P.287 掲載の参考文献

1) Bobrie G et al : Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 291 : 1342-1349, 2004

2) Obara T et al : Definition of masked hypertension. J Hypertens 25 : 1512-1513, 2007

P.289 掲載の参考文献

1) Julius S et al ; Trial of Preventing Hypertension (TROPHY) Study Investigators : Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 : 1685-1697, 2006

2) Nakaya H et al : Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 12 : 659-666, 2001

3) Nakaya H et al : Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron 91 : 710-718, 2002

P.291 掲載の参考文献

1) Julius S et al ; VALUE trial group : Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine : the VALUE randomised trial. Lancet 363 : 2022-2031, 2004

2) Weber MA et al : Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363 : 2049-2051, 2004

[ 脳血管障害 ]

P.295 掲載の参考文献

1) Markus HS et al : Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection : the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) triaL Circulation 111 : 2233-2240, 2005

2) Diener HC et al ; MATCH Investigators : Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischaemic attach in high-risk patients (MATCH) : randomized, double-blind, Placebo-controlled trial. Lancet 364 : 331-337, 2004

P.297 掲載の参考文献

1) ESPRIT Study Group et al : Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT) : randomized controlled trial. Lancet 367 : 1665-1673, 2006

P.299 掲載の参考文献

1) Hennerici MG et al ; ESTAT investigators : Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial : a randomised controlled trial. Lancet 368 : 1871-1878, 2006

2) Sherman DG et al : ESTAT investigators : Intravenous ancrod for treatment of acute ischemic stroke : the STAT study : a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 283 : 2395-2403, 2000

P.301 掲載の参考文献

1) Rothwell PM et al ; Early use of Existing Preventive Strategies for Stroke (EXPRESS) study : Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study) : a prospective population-based sequential comparison. Lancet 370 : 1432-1442, 2007

P.303 掲載の参考文献

1) Mayer SA et al ; FAST Trial Investigators : Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 358 : 2127-2137, 2008

2) Mayer SA et al ; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators : Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352 : 777-785, 2005

3) Kissela BM et al : Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage. BMC Neurol 8 : 17, 2008

4) Diringer MN et al : Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke 39 : 850-856, 2008

5) Narayan RK et al ; rFVIIa Traumatic ICH Study Group : Recombinant factor VIIA in traumatic intracerebral hemorrhage : results of a dose-escalation clinical trial. Neurosurgery 62 : 776-786, 2008

P.305 掲載の参考文献

1) Schillinger M et al : lnflammation and Carotid Artery--Risk for Atherosclerosis Study (ICARAS). Circulation 111 : 2203-2209, 2005

2) Ishikawa J et al : Low-grade inflammation is a risk factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives : the Jichi Medical School ABPM Study, wave 1. Stroke 38 : 911-917, 2007

3) Ridker PM et al : Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 : 2195-2207, 2008

P.307 掲載の参考文献

1) Muir KW et al ; Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators : Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial) : randomised controlled trial. Lancet 363 : 439-445, 2004

2) Izumi Y et al : Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 11 : 1025-1030, 1991

3) Muir KW et al : A randomised, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Strohe 26 : 183-188, 1995

4) Aslanyan S et al ; IMAGES Study Investigators : Magnesium for treatment of acute lacunar stroke syndromes : further analysis of the IMAGES trial. Stroke 38 : 1269-1273, 2007

P.309 掲載の参考文献

1) Diener HC et al ; MATCH investigators : Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH) : randomised, double-blind, placebo-controlled triaL Lancet 364 : 331-337, 2004

2) CAPRIE Steering Committee : A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 : 1329-1339, 1996

3) The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators : Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 : 494-502, 2001

4) Steinhubl SR et al : Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention : a randomized controlled trial. JAMA 288 : 2411-2420, 2002

5) Bhatt DL et al : Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 : 1706-1717, 2006

P.311 掲載の参考文献

1) Ogawa A et al ; MELT Japan Study Group : Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke : the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 38 : 2633-2639, 2007

2) del ZopPo GJ et al : PROACT : a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 29 : 4-11, 1998

3) Furlan A et al : lntra-arterial prourokinase for acute ischemic stroke. The PROACT II study : a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282 : 2003-2011, 1999

P.313 掲載の参考文献

1) Sherman DG et al ; PREVAIL Investigators : The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study) : an open-label randomised comparison. Lancet 369 : 1347-1355, 2007

P.315 掲載の参考文献

1) Sacco RL et al ; PRoFESS Study Group : Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359 : 1238-1251, 2008

2) Yusuf S et al ; PRoFESS Study Group : Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359 : 1225-1237, 2008

P.317 掲載の参考文献

1) Yadav JS et al ; Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy Investigators : Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 351 : 1493-1501, 2004

2) Gurm HS et al ; SAPPHIRE Investigators : Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med 358 : 1572-1579, 2008

3) SPACE Collaborative Group et al : 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients : a randomised non-inferiority trial. Lancet 368 : 1239-1247, 2006

4) Mas JL et al ; EVA-3S Investigators : Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 355 : 1660-1671, 2006

5) Hobson RW 2nd et al ; CREST Investigators : Carotid artery stenting is associated with increased complications in octogenarians : 30-day stroke and death rates in the CREST lead-in phase. J Vasc Surg 40 : 1106-1111, 2004

P.320 掲載の参考文献

1) Wahlgren N et al ; SITS-MOST investigators : Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) : an observational study. Lancet 369 : 275-282, 2007

2) Hill MD et al ; Canadian Alteplase for Stroke Effectiveneess Study (CASES) Investigators : Thrombolysis for acute ischemic stroke : results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 172 : 1307-1312, 2005

P.324 掲載の参考文献

1) Amarenco P et al ; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators : High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 : 549-559, 2006

2) Goldstein LB et al ; SPARCL Investigators : Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 70 : 2364-2370, 2008

P.327 掲載の参考文献

1) Chimowitz MI et al ; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators : Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352 : 1305-1316, 2005

[ 腎機能障害 ]

P.331 掲載の参考文献

1) Wanner C et al ; German Diabetes and Dialysis Study Investigators : Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 : 238-248, 2005

P.333 掲載の参考文献

1) Bakris G et al ; AMADEO Study Investigators : Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 74 : 364-369, 2008

P.335 掲載の参考文献

1) Solomon RJ et al ; Investigators of the CARE Study : Cardiac Angiography in Renally Impaired Patients (CARE) study : a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 115 : 3189-3196, 2007

2) Aspelin P et al : Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348 : 491-499, 2003

P.337 掲載の参考文献

1) Fujita T et al ; Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Disease (CARTER) Study Investigators : Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 72 : 1543-1549, 2007

2) Jamerson K et al ; ACCOMPLISH Trial Investigators : Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N EnglJ Med 359 : 2417-2428, 2008

3) Bakris GL et al ; GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators : Effects of different ACE inhibitor combinations on albuminuria : results of the GUARD study. Kidney Int 73 : 1303-1309, 2008

P.339 掲載の参考文献

1) Singh AK et al : CHOIR Investigators : Correction of anemia with epoetin α in chronic kidney disease. N Engl J Med 355 : 2085-2098, 2006

2) Besarab A et al : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and erythropoietin. N Engl J Med 339 : 584-590, 1998

3) Druke TB et al ; CREATE Investigators : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 : 2071-2084, 2006

4) Regidor DL et al : Associations between changes in hemoglobin and administrered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 : 1181-1191, 2006

5) Szczech LA et al : Secondary analysis of the CHIOR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int 74 : 791-798, 2008

P.341 掲載の参考文献

1) Barnett AH et al ; Diabetics Exposed to Telmisartan and Enalapril Study Group : Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351 : 1952-1961, 2004

2) Barnett AH : Preventing renal complications in diabetic patients : the Diabetics Exposed to Telmisartan And enalapril (DETAIL) study. Acta Diabetol 42 (Supple 1) : S42-S49, 2005

P.343 掲載の参考文献

1) Jamison RL et al ; Veterans Affairs Site Investigators : Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease : a randomized controlled trial. JAMA 298 : 1163-1170, 2007

P.345 掲載の参考文献

1) Asselbergs FW et al ; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators : Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110 : 2809-2816, 2004

2) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus : results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355 : 253-259, 2000

P.347 掲載の参考文献

1) Ruggenenti P et al ; REIN-2 Study Group : Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2) : multicentre, randomised controlled trial. Lancet 365 : 939-946, 2005

2) Randomised, placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349 : 1857-1863, 1997

3) Ruggenenti P e'al : Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril : REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352 : 1252-1256, 1998

4) Ruggenenti P et al : Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354 : 359-364, 1999

[ 脂質異常症動脈硬化 ]

P.351 掲載の参考文献

1) Kastelein JJ et al ; ENHANCE Investigators : Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 : 1431-1443, 2008

P.353 掲載の参考文献

1) Pedersen TR et al ; Incremental Decrease in End Points Through Agressive Lipid Lowering (IDEAL) Study Group : High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction : the IDEAL study : a randomized controlled trial. JAMA 294 : 2437-2445, 2005

2) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease : the Scandinavian Simvastatin Survival Study (4S). Lancet 344 : 1383-1389, 1994

P.355 掲載の参考文献

1) Yokoyama M et al ; Japan EPA lipid intervention study (JELIS) Investigators : Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised open-label, blinded endpoint analysis. Lancet 369 : 1090-1098, 2007

2) Tanaka K et al : Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients : subanalysis of the JELIS trial. Strohe 39 : 2052-2058, 2008

P.358 掲載の参考文献

1) Crouse JR 3rd et al ; METEOR Study Group : Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis : the METEOR Trial. JAMA 297 : 1344-1353, 2007

2) Crouse JR 3rd et al ; Measuring Effects on intima media Thickness : an Evalution Of Rosuvastatin study group : Measuring Effects on intima media Thickness : an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study. Cardiovasc Drugs Ther 18 : 231-238, 2004

P.361 掲載の参考文献

1) Kastelein JJ et al ; RADIANCE 1 Investigators : Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 : 1620-1630, 2007

2) Bots ML et al ; RADIANCE 2 Investigators : Torcetrapib and carotid intima-media thickness in mixed dyslipidemia (RADIANCE 2) : a randomised, double-blind study. Lancet 370 : 153-160, 2007

3) Nissen SE et al ; ILLUSTRATE Investigators : Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 : 1304-1316, 2007

P.364 掲載の参考文献

1) Bots ML et al ; RADIANCE 2 Investigators : Torcetrapib and carotid intima-media thickness in mixed dyslipidemia (RADIANCE 2) : a randomised, double-blind study. Lancet 370 : 153-160, 2007

2) Kastelein JJ et al ; RADIANCE 1 Investigators : Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 : 1620-1630, 2007

3) Vergeer M et al : Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity : a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 118 : 2515-2522, 2008

P.367 掲載の参考文献

1) Goto S : Cardiovascular risk factors in patients at high risk of atherothrombosis : what can be learned from registries? Thromb Haemost 100 : 611-613, 2008

2) Ohman EM et al ; REACH Registry Investigators : The REduction of Atherothrombosis for Continued Health (REACH) Registry : an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 151 : 786. e1-e10, 2006

3) Bhatt DL et al ; REACH Registry Investigators : International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 : 180-189, 2006

4) Yamazaki T et al ; REACH Registry Investigators : Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J 71 : 995-1003, 2007

5) Steg PG et al ; REACH Registry Investigators : One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297 : 1197-1206, 2007

6) Goto S et al ; REACH Registry Investigators : Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 156 : 855-863, 2008

P.369 掲載の参考文献

1) Despres JP et al ; Rimonabant in Obesity-Lipids Study Group : Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 : 2121-2134, 2005

P.371 掲載の参考文献

1) Pi-Sunyer FX et al ; RIO-North America Study Group : Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients : RIO-North America : a randomized controlled trial. JAMA 295 : 761-775, 2006

書評

書評を投稿する

最近チェックした商品履歴

Loading...